[thw_title_shortcode alignment=”center” title=”Conference Schedule” title_heading=”h3″ title_size=”36″ title_line_height=”36″ title_weight=”700″ title_margin=”0 0 15px” sub_title_weight=””]
[thw_title_shortcode alignment=”center” title=”Wednesday, February 14th, 2018″ title_heading=”h3″ title_size=”36″ title_line_height=”36″ title_color=”#ffffff” title_weight=”700″ title_margin=”0 0 15px” sub_title_weight=””]

6:30 am – 5:15 pm

Registration Open

Grande Foyer

7:00 am – 8:00 am

Moderator Orientation & Breakfast

Marina 4

7:00 am – 8:00 am

Continental Breakfast

Grande Foyer

8:00 – 8:15 am

President’s Address
David Schlichting, LPN

Grande Ballroom B/C

Session 101

8:15 – 9:15 AM

Amyloidosis and Clinical Research in Orphan Diseases

Dr. Stephen Heitner, MBBCh (MD), FASE, FACC

Amyloidosis may not be as rare as you think. There is a lack of disease identification. This presentation will help raise awareness and educate on treatment strategies developed from clinical research.

Learning Objective:

Describe Amyloidosis diagnosis and subtyping, genetics, clinical manifestations, and current clinical research opportunities.

Grande Ballroom B/C

General Session 1

Session 102

9:15 – 10:15 AM

Robin Weber Immunology Symposium/Immunotherapy, the Next Generation of Skin Cancer Treatment – AANP

Grace Chung, DNP, FNP-BC

We are in a revolutionary new era of immunotherapy for skin cancers where immunotherapy has opened the doors to find additional treatment options for advanced and unresectable skin cancers. This paradigm shift in skin cancer treatment is demanding dermatology providers to better understand about immunotherapy. Therefore, the goal of this presentation is to facilitate understanding of various types of immunotherapy and their potential side effects in the treatment of melanoma and non-melanoma skin cancers.

Learning Objectives:

1 – Describe the various types of immunotherapeutic agents.

2 – Incorporate these agents into the planning and treatment of advanced unresectable skin cancers.

Grande Ballroom B/C

General Session 2

10:15 am – 12:15 pm

Grand opening of exhibit Hall
Join us for the official ribbon cutting ceremony to kick off the opening of the exhibit hall. A wide assortment of products, equipment, and services will be displayed by the leading suppliers of the dermatology industry.


12:15 pm – 1:30 pm

Luncheon Theater (All are invited)

Sponsored by Regeneron/Sanofi

DUPIXENT® (dupilumab) FDA-Approved

Speaker – Lakshi M. Aldredge, MSN, RN, ANP-BC 

Grande Ballroom B/C

1:00 pm – 5:00 pm

National Psoriasis Foundation APREP 

In conjunction with the 2018 Dermatology Nurses’ Association conference, the Psoriasis Recognition Program is designed to help enhance your skills in caring for those with psoriasis. Physician assistants and nurse practitioners can attend a regional Recognition Program meeting to earn up to 4.00 CME credits. After completing this program, attendees will be formally recognized as up-to-date in the latest psoriasis treatments. *Additional Registration Required*

Physician Assistants, Nurse Practitioners, RNs and other allied health professionals

Marina 3

Session 111

1:30 – 2:30 PM

Cutaneous Lymphomas: Intersecting Clinical Care and Community Part 1 – AANP

Marianne Tawa, MSN, RN, ANP
Susan McCann, MSN, RN, DNC

This cutting edge Part I/II presentation series will introduce and carry the audience through the world of cutaneous T and B cell lymphomas. Learners will gather critical tips on assessment and diagnosis of patients suspected of cutaneous lymphoproliferative malignancy. Implementing and managing patients exposed to skin directed treatment options such as, topical corticosteroids, nitrogen mustard, phototherapy, and radiation will become strategic. A brief overview of systemic therapies will be included. Select case studies will be incorporated to solidify the teaching points. The ever so vital role of community engagement and advocacy in rare diseases such as CTCL and Cutaneous B cell Lymphoma will be intertwined.

Learning Objectives:

1 – Describe the physical examination features and symptom complex associated with patch/plaque/tumor/erythroderma associated with CTCL.

2 – Identify two key indications for delivery of skin directed and systemic therapies in patients with persistent/progressive CTCL, elaborating safety monitoring requirements.

3 – Identify educational and advocacy resources for the CTCL patient population.

Nautilus 5

Concurrent Session

Session 112

1:30 – 2:30 PM

Mohs and Reconstructive Surgery for Common and Uncommon Malignancies of the Skin – AANP

Stanislav Tolkachjov, MD

This is an overview of the Mohs micrographic surgery technique focusing on treatment of common and uncommon malignancies and complex reconstruction. It will also feature pearls for the role of multidisciplinary care team of nurses and physician extenders during surgery.

Learning Objectives:

1 – Identify common and uncommon skin malignancies.

2 – IDescribe treatment of common and uncommon skin malignancies.

3 – Educate patient on the reconstructive surgery after Mohs surgery.

Nautilus 3&4

Concurrent Session

Session 113

1:30 – 2:30 PM

Pharmacologic Management of Dermatophyte Infections in Humans – AANP

Theresa Coyner, MSN, NP
Katrina Masterson, DNP, RN, FNP-BC, DCNP

The pharmacologic management of dermatophyte infections in humans with systematic and topical treatment options.

Learning Objectives:

1 – Identify appropriate pharmacologic management of dermatophyte infections of the hair and scalp regarding mechanism of actions, dosing, medication interactions, adverse effects, and monitoring guidelines.

2 – Identify clinical signs of dermatophyte infections.

3 – Identify appropriate diagnostics of dermatophyte infections.

Grande Ballroom A

Concurrent Session

2:30 – 4:00 pm

Exhibits Open/Poster Viewing

Help celebrate the JDNA’s 10th Year Anniversary!
Visit the JDNA booth in the exhibit hall where you can meet our Editor-In-Chief, Angela Borger, and enjoy a piece of celebration cake with her and our publishers.


Session 121

4:00 – 5:00 PM

Acne Overview: Epidemiology, Morphology, Treatment, and Patient Education – AANP

Heather Onoday, MN, RN, FNP
Sarah Neider, MA

The presentation will provide the clinical team member with an overview of acne in order to better understand the disease to improve patient care and treatment compliancy.

Learning Objectives:

1 -Describe the epidemiology and morphology of acne as well as the most current treatments for the condition.

2 – Educate the patient on the treatment for acne as well as the necessity for compliance to achieve optimum outcomes.

Nautilus 3&4

Concurrent Session

Session 122

4:00 – 5:00 PM

Advancing Stepwise Care of Atopic Dermatitis: Basics to Biologics – AANP

Noreen Heer Nicol, PhD, RN, FNP, NEA-BC

Learning Objectives:

1 – Define atopic dermatitis and recognize it as part of the atopic triad.

2 – Summarize the skin barrier dysfunction and immunologic process involved in atopic dermatitis pathogenesis.

3 – Identify step-wise management of atopic dermatitis following international and national guidelines of care.

4 – Explore evolving therapies and their treatment role.

Grande Ballroom A

Concurrent Session

Session 123

4:00 – 5:00 PM

Poster Presentations

Multiple nurses will present their poster research.

Nautilus 5

Concurrent Session

5:00 – 6:00 pm

Wine & Cheese PT | Janssen Biotech, Inc.

(First come first serve, Limited to 100)

A First-in-Class Novel Biologic that Selectively Blocks Interleukin-23 (IL-23)
Wendy Cantrell, CRNP, DNP

Commercial Support Provided by Janssen Biotech, Inc.

Nautilus 1 & 2

6:00 – 7:00 pm

First-Time Attendee Reception

All first-time attendees are welcome. Join the DNA Board of Directors and the Program Planning Committee for refreshments while networking with DNA leaders. Please select this event when completing your registration.

Shoreline (Outside)

Alternate location: Grande Foyer